초록 ▼

The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formul

The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.

대표청구항 ▼

1. A method of treating muscle spasticity in a human, comprising the step of administering by injecting into a muscle of said human patient a dose between 20 to 2250 picograms of botulinum toxin type A per injection cycle, from a pharmaceutical formulation comprising botulinum toxin type A and zinc-

1. A method of treating muscle spasticity in a human, comprising the step of administering by injecting into a muscle of said human patient a dose between 20 to 2250 picograms of botulinum toxin type A per injection cycle, from a pharmaceutical formulation comprising botulinum toxin type A and zinc-saturated human serum albumin in an amount greater than 500 micrograms human serum albumin per 100 LD50 Units botulinum toxin type A, wherein the administration of said formulation produces a therapeutic muscle weakness in said human patient, and wherein said formulation has specific activity between 100 and 250 LD50 Units per nanogram botulinum toxin type A. 2. The method of claim 1 wherein said muscle is the flexor digitorum profundus muscle, and said dose is between 20 to 450 picograms of botulinum toxin type A per injection cycle. 3. The method of claim 1 wherein said muscle is the flexor digitorum sublimus muscle, and said dose is between 20 to 450 picograms of botulinum toxin type A per injection cycle. 4. The method of claim 1 wherein said muscle is the flexor carpii ulnaris muscle, and said dose is between 20 to 450 picograms of botulinum toxin type A per injection cycle. 5. The method of claim 1 wherein said muscle is the flexor carpii radialis muscle, and said dose is between 35 to 725 picograms of botulinum toxin type A per injection cycle. 6. The method of claim 1 wherein said muscle is the biceps brachii muscle, and said dose is between 100 to 2250 picograms of botulinum toxin type A per injection cycle. 7. The method of claim 1 wherein said zinc-saturated human serum albumin enhances an endopeptidase activity of said botulinum toxin type A. 8. The method of claim 1 wherein said zinc-saturated human serum albumin enhances a denervating effect of said botulinum toxin type A.